Formidable Asset Management
NBIX icon

Formidable Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Formidable Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$428K Buy
+3,021
New +$486K 0.06% 266
2019
Q2 		– Sell
-4,400
Closed -$386K – 301
2019
Q1 		$386K Buy
+4,400
New +$368K 0.15% 115

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Formidable Asset Management's NBIX Position: Q3 2026 in Review

Formidable Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 3,021 shares worth $428K. The stake represents 0.06% of the portfolio and ranks #266 among its holdings. This is a return to the name: Formidable Asset Management previously reported a position in NBIX as recently as Q1 2019.

Formidable Asset Management first reported a position in NBIX in Q1 2019 and has held it in 2 quarters since. 361 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Formidable Asset Management held 3,021 shares of Neurocrine Biosciences worth $428K as of Q3 2026.
  • Neurocrine Biosciences was a new Formidable Asset Management position in Q3 2026.
  • Neurocrine Biosciences made up 0.06% of Formidable Asset Management's portfolio in Q3 2026, its #266 holding.
  • Formidable Asset Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 2 quarters since.
  • 361 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Formidable Asset Management's 13F filing for Q3 2026, filed 3 Nov 2026.